Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir to prevent mother-to-child transmission of HTLV-1
RBR-22csg9kPhase 3Not yet recruiting
- Sponsor
- Fiocruz Bahia
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dolutegravir in human T-cell lymphotropic virus type 1 infection (HTLV-1) (2 arms), sponsored by Fiocruz Bahia. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
dolutegravir
03
Conditions
human T-cell lymphotropic virus type 1 infection (HTLV-1)
Beyond the preview
Go deeper on RBR-22csg9k.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-22csg9k.